Bladder Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight's, "Bladder Cancer Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Bladder Cancer Research. Learn more about our innovative pipeline today! @ Bladder Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Bladder Cancer Pipeline Report

* May 2024:- Eli Lilly and Company- The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.
* May 2024- Merck Sharp & Dohme LLC- The purpose of this study is to assess the safety and efficacy of V940 in combination with pembrolizumab (MK-3475) compared to pembrolizumab alone as an adjuvant treatment for participants with pathologic high-risk muscle-invasive urothelial carcinoma (MIUC) after radical resection. The primary study hypothesis is that V940 in combination with pembrolizumab results in a superior disease-free survival (DFS) as assessed by the investigator compared to pembrolizumab alone in participants with high-risk MIUC after radical resection.
* May 2024:- Ferring Pharmaceuticals- ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States. Multi-center, prospective non-interventional study to collect data on the early use of ADSTILADRIN in the US. Data will be collected from participants, caregivers and prescribing physicians in a real-world setting.
* DelveInsight's Bladder Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Bladder Cancer treatment.
* The leading Bladder Cancer Companies working in the market include UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others.
* Promising Bladder Cancer Therapies in the various stages of development include Atezolizumab, PGV001, VAX014, BCG Vaccine, Oncofid-P-B, Oncofid-P-B, and others.

Stay informed about the cutting-edge advancements in Bladder Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Bladder Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Bladder cancer Emerging Drugs Profile

UGN-102: UroGen Pharma Ltd.

UGN-102 (mitomycin) for intravesical solution is an investigational drug formulation of mitomycin. It is been developed by utilizing UroGen's proprietary RTGel Registered technology which is a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting. Currently it is in Phase III stage of clinical trial for the treatment of Bladder Cancer.

APL 1202 : Asieris Pharmaceuticals

APL-1202 is an orally available reversible MetAP2 Inhibitor with anti-angiogenic, anti-tumor activities and can also modulate tumor immune microenvironment. It is currently in registration clinical trials in China, either as single agent as first-line treatment for patients with intermediate-risk non-muscle invasive bladder cancer (NMIBC), or in combination with a chemotherapy as second-line treatment in patients with intermediate and high-risk chemo-refractory NMIBC. Currently, the drug is being evaluated in the Phase III stage for Bladder Cancer.

Trilaciclib: G1 Therapeutics, Inc.

Trilaciclib, is a first-in-class therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. It is a transient IV-administered CDK4/6 inhibitor, a novel therapeutic approach which is given before chemotherapy that temporarily blocks progression through the cell cycle. Currently the drug is being evaluated in Phase II for the treatment of Bladder Cancer.

Catumaxomab: LintonPharm Co.,Ltd.

Catumaxomab is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcR binding at the same time. The drug kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. The drug is in Phase I/II stage of clinical trials for the treatment of bladder cancer.

VAX 014: Vaxiion Therapeutics

VAX014 is a novel rBMC-based oncolytic immunotherapy. VAX014is a first-in-class tumor-targeted oncolytic agent based on Vaxiion's proprietary rBMC technology. It works by specifically targeting and delivering a novel fast-acting pre-formed oncolytic protein toxin directly to tumor cells that express either 31 or 51 integrin(s), both commonly found to be selectively expressed in many solid tumor types. The drug is in Phase I stage of clinical trials for the treatment of bladder cancer.

Learn more about Bladder Cancer Drugs opportunities in our groundbreaking Bladder Cancer Research and development projects @ Bladder Cancer Unmet Needs [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical

Bladder Cancer Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

Discover the latest advancements in Bladder Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Bladder Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Bladder Cancer Pipeline Report

* Coverage- Global
* Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Bladder Cancer Companies- UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others
* Bladder Cancer Therapies- Atezolizumab, PGV001, VAX014, BCG Vaccine, Oncofid-P-B, Oncofid-P-B, and others.

For a detailed overview of our latest research findings and future plans, read the full details of Bladder Cancer Pipeline on our website @ Bladder Cancer Drugs and Companies [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Bladder Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* UGN-102: UroGen Pharma Ltd.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Trilaciclib: G1 Therapeutics, Inc.
* Early Stage Products (Phase I)
* VAX 014: Vaxiion Therapeutics
* Inactive Products
* Bladder Cancer Key Companies
* Bladder Cancer Key Products
* Bladder Cancer - Unmet Needs
* Bladder Cancer - Market Drivers and Barriers
* Bladder Cancer - Future Perspectives and Conclusion
* Bladder Cancer Analyst Views
* Bladder Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bladder-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.